A detailed history of Cooper/Haims Advisors, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Cooper/Haims Advisors, LLC holds 450 shares of LLY stock, worth $409,198. This represents 0.23% of its overall portfolio holdings.

Number of Shares
450
Previous 627 28.23%
Holding current value
$409,198
Previous $487,000 16.43%
% of portfolio
0.23%
Previous 0.29%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$724.87 - $909.04 $128,301 - $160,900
-177 Reduced 28.23%
450 $407,000
Q1 2024

May 10, 2024

BUY
$592.2 - $792.28 $117,255 - $156,871
198 Added 46.15%
627 $487,000
Q4 2023

Feb 13, 2024

SELL
$525.19 - $619.13 $71,425 - $84,201
-136 Reduced 24.07%
429 $250,000
Q3 2023

Nov 09, 2023

BUY
$434.7 - $599.3 $245,605 - $338,604
565 New
565 $303,000
Q1 2019

Apr 26, 2019

BUY
$111.31 - $131.02 $2.4 Million - $2.82 Million
21,561 New
21,561 $2.8 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $864B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Cooper/Haims Advisors, LLC Portfolio

Follow Cooper/Haims Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cooper/Haims Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cooper/Haims Advisors, LLC with notifications on news.